Leilei Han

Leilei Han

Auto-generated profile, based on publicly available information

Leilei Han

Department of Cardiology, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, 330006, China, ncu.edu.cn

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2025 in Mediators of Inflammation
Verified
Journal Article
Open access
KLKai Li
Kai Li
JFJie Feng
Jie Feng
MLMeng Li
Meng Li
LHLeilei Han
Leilei Han
YWYanqing Wu
Yanqing Wu
Endothelial dysfunction is a significant factor in the pathogenesis of various diseases. In pathological states, endothelial cells (ECs) undergo activation, resulting in dysfunction characterized by the stimulation of inflammatory responses, oxidative stress, cell proliferation, blood coagulation, and vascular adhesions. Interleukin‐35 (IL‐35), a novel member of the IL‐12 family, is primarily secreted by regulatory T cells (Tregs) and regulatory B cells (Bregs). The role of IL‐35 in immunomodulation, antioxidative stress, resistance to apoptosis, control of EC activation, adhesion, and angiogenesis in ECs remains incompletely understood, as the specific mechanisms of IL‐35 action and its regulation have yet to be fully elucidated. Therefore, this systematic review aims to comprehensively investigate the impact of IL‐35 on ECs and their physiological roles in a range of conditions, including cardiovascular diseases, tumors, sepsis, and rheumatoid arthritis (RA), with the objective of elucidating the potential of IL‐35 as a therapeutic target for these ailments.

1 January 2026 in Mediators of Inflammation
Verified
Journal Article
Open access
FXFeng Xie
Feng Xie
JFJie Feng
Jie Feng
KLKai Li
Kai Li
YCYi Chen
Yi Chen
LHLeilei Han
Leilei Han
YWYanqing Wu
Yanqing Wu
Background: Pulmonary hypertension (PH) is a serious disease that manifests itself as elevated pressure within the pulmonary arteries. The onset of PH is usually insidious, and if left untreated, it may lead to heart failure and even life‐threatening conditions. Recent studies have shown that sophocarpine (SOP) has significant effects on antioxidant, anti‐inflammatory, antifibrotic, and hemodynamic improvement, and it may become an emerging drug for the treatment of PH. However, the specific mechanism of action of SOP still requires further experimental validation. Methods: We established in vivo and in vitro models of PH and treated them with varying concentrations of SOP. To visualize the changes in rats and cells, we used scratch assay, flow cytometry, Western blotting, pulmonary artery pressure measurement, biochemical analysis, enzyme‐linked immunosorbent assay (ELISA), ultrasound scanning, hematoxylin and eosin (HE) staining, and Masson’s trichrome staining. Results: Our results showed that SOP significantly alleviated the inflammatory response and apoptosis induced by PH, reduced pulmonary artery pressure, and restored the balance of pulmonary artery remodeling. These effects were found to be effective in alleviating PH. Conclusion: Our study provides clear evidence that SOP has a significant protective effect in the PH model and is expected to be a promising therapeutic agent for PH.